stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Net income
Tarsus Pharmaceuticals, Inc.'s net income for fiscal 2025 was −$66.4M, compared with −$115.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$702.2M. Over the past ten years it has ranged from −$135.9M (fiscal 2023) to $0.00 (fiscal 2017); the current reading is higher than 33% of that period. Tarsus Pharmaceuticals, Inc. ranks 597th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$66.4M | — |
| FY2024 | −$115.6M | — |
| FY2023 | −$135.9M | — |
| FY2022 | −$62.1M | — |
| FY2021 | −$13.8M | — |
| FY2020 | −$26.8M | — |
| FY2019 | −$4.7M | — |
| FY2018 | −$1.3M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$668.3M | — |
| Jun 2026 | −$18.6M | — |
| Mar 2026 | −$7.0M | — |
| Dec 2025 | −$8.4M | — |
| 25 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| TLX Telix Pharmaceuticals Limited compare | $31.7M |
| ELVN Enliven Therapeutics, Inc. compare | −$105.9M |
| CELC Celcuity, Inc. compare | −$226.5M |
| DNLI Denali Therapeutics Inc. compare | −$314.4M |
| VRDN Viridian Therapeutics, Inc. compare | −$453.6M |
| DYN Dyne Therapeutics, Inc. compare | −$519.4M |
| VKTX Viking Therapeutics, Inc. compare | −$627.2M |
| TARS Tarsus Pharmaceuticals, Inc. | −$702.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TARS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement